The 10-year overall mortality rate among men with non-metastatic prostate cancer(PCa) is about 3 times higher than PCa-specific mortality (PCSM), accordingto investigators in Norway.
Using data from the Norwegian Prostate Cancer Registry, Kirsti Aas, MD, ofBaerum Hospital in Drammen, and colleagues calculated the 10-year overall mortalityand PCSM rates among 3449 men diagnosed with non-metastatic PCa during2004-2005. Of these, 913 underwent radical prostatectomy, 1334 underwentradiotherapy, and 1202 had no local treatment.
The 10-year overall mortality andPCSM rates were 25.5% and 8.5%, respectively, the investigators reported onlineahead of print in Urology. Among low-risk and high-risk patients, the likelihoodof dying from causes other than PCa was 8-fold and 2-fold higher compared withdeath from PCa. “Patients with high-risk factors seemed to benefit the most fromlocal treatment,” the researchers wrote.